Connect with us

Published

on

The new drug looked so promising except for that one warning sign.

This story also ran on Fortune. It can be republished for free.

At the American College of Rheumatologys annual meeting in 2008, Duke Universitys Dr. John Sundy proudly announced that pegloticase, a drug hed helped develop, was astoundingly effective at treating severe gout, which affects perhaps 50,000 Americans. In about half of those who had taken it, the drug melted away the crystalline uric acid deposits that encrusted their joints to cause years of pain, immobility, or disfigurement.

But Sundy also disclosed an unsettling detail: In one clinical trial, patients who got the drug were more likely to develop heart problems than those who didnt. The day after Sundys talk, the stock price of Savient Pharmaceuticals, which developed the drug with Duke scientists, plunged 75%.

That danger signal would disappear in later studies, and the FDA approved pegloticase, under the trade name Krystexxa, two years later. But the small biotech company never recovered. In 2013, Savient was sold at auction to Crealta, a private equity venture created for the purpose, for $120 million.

Two years later, a young company now called Horizon Therapeutics bought Crealta and its drug portfolio for $510 million.

Even at that price, it proved a good deal. Krystexxa brought in $716 million in 2022 and was expected to earn $1 billion annually in coming years.

Although Horizon says it now has 20 drugs under development, in its 15 years of existence it has yet to license a product it invented. Yet the company has managed to assemble a war chest of lucrative drugs, in the process writing a playbook for how to build a modern pharmaceutical colossus.

As the White House and both parties in Congress grapple with reining in prescription drug prices, Horizons approach reveals just how difficult this may be.

Horizons strategy has paid off handsomely. Krystexxa was just one of the many shiny objects that attracted Amgen, a pharmaceutical giant. Amgen announced in December that it intends to buy Horizon for $27.8 billion, in the biggest pharmaceutical industry deal announced in 2022.

Horizons CEO, Tim Walbert, who will reportedly get around $135 million when the deal closes, has mastered a particular kind of industry expertise: taking drugs invented and tested by other people, wrapping them expertly in hard-nosed marketing and warm-hued patient relations, raising their prices, and enjoying astounding revenues.

Hes done this with unusual finesse courting patients with concierge-like attention and engaging specialist clinicians with lunches, conferences, and research projects, all while touting his own experience as a patient with a rare inflammatory disease. Walberts company has been particularly adept at ensuring that insurers, rather than patients, bear the costly burdens of his drugs.

A federal prosecutor in 2015 began examining allegations that Horizons patient assistance program had worked with specialty pharmacies to evade insurers efforts to shun Horizons expensive drugs. A separate probe opened in 2019 over alleged kickbacks to pharmacy benefit managers, companies that negotiate to get Horizons drugs covered by insurers. Those investigations appear to be no longer active, Horizon spokesperson Catherine Riedel said. The company this year disclosed a third probe, concerning methods the company allegedly used to get prior authorization of its drugs. Justice officials did not respond to requests for comment on the investigations. Email Sign-Up

Subscribe to KFF Health News' free Morning Briefing. Your Email Address Sign Up

An Injection of Marketing

To help sell its drugs, Horizon blankets specialist physicians with marketing and peer-to-peer appeals. Its payments to physicians for things like consulting, speeches, and meals totaled $8.7 million in 2021, compared with the $10 million it paid them for research, federal records show. By contrast, Seagen, a biotech company of roughly the same size, paid doctors a total of $116 million, with nearly $112 million of that pegged for research. Riedel said Horizons marketing and educational approaches were necessarily unique because of the challenges of treating rare and neglected diseases.

Walbert launched Horizon in 2008 in the Chicago area by combining and refashioning generic drugs into single pills. Duexis, Horizons first drug, is a mixture of generic Motrin and Pepcid. Its Vimovo combines generic Aleve and Nexium. In a 2017 article, a ProPublica reporter described being prescribed Vimovo for a shoulder injury. It cost him nothing, but his insurer was billed $3,252 for pills that together cost about $40 for a months supply in generic form. Horizon sold more than $57 million worth of Vimovo that year.

In 2014 and 2015, respectively, Horizon picked up two relatively new drugs that had no generic versions: the immunosuppressant Actimmune and Ravicti, which treats a rare genetic disorder. Soon Horizon was charging more than $50,000 a month for each, placing Actimmmune fourth and Ravicti second on GoodRxs 2020 list of the most expensive U.S. drugs.

Horizons net sales soared from $20 million in 2012 to $981 million in 2016; Walberts pay package followed suit, topping an astronomical $93.4 million in 2015 in salary and stock. Stock analysts questioned the long-term soundness of a strategy of simply selling old drugs for mind-boggling prices, but Walbert was using the cash to refashion the company as a rare-diseases franchise.

His approach would make Walbert a darling of pharmaceutical investors and his board, which lavished him with over $20 million in compensation each of the past three years. While most biotechs and startups borrow heavily from venture capital to do science and have no idea how to develop and market a drug, Walbert got cash coming in quickly. He did it backwards, said Annabel Samimy, an analyst at Stifel Financial Corp. Horizon built commercial platforms before they got into drug development.

Generating robust sales of what sounded like not very interesting drugs allowed Walbert to start a company on not very much, said Oppenheimer analyst Leland Gershell. All the while, Horizon funded and cultivated the patient advocacy groups that can help lobby for a drug to be approved by the FDA and placed on insurers formularies, the lists of drugs health plans cover for patients.

Capitalizing on His Own Illness?

As Walbert and his spokespeople often point out, Walbert and his youngest son suffer from a rare disease, and Walbert also has an autoimmune disease. Walbert wont name the diseases, but has said hes taken the anti-inflammatory injectable Humira since 2003 the year he led that drugs commercial launch as a vice president at Abbott Laboratories. Humira has become the bestselling drug in history, with about $200 billion in all-time global sales.

In 2014, Walbert moved Horizons headquarters to Ireland, which nearly halved its tax rate. A year later it gained control of Krystexxa, and in 2017 it bought, for $145 million, a failing company that produced Tepezza, a drug for thyroid eye disease, which causes unsightly eye bulging and pain.

Tepezza quickly became a blockbuster, with $3.6 billion in total sales in 2021 and 2022. The company conducted additional clinical research on both Tepezza and Krystexxa, but it also spent heavily promoting these and other drugs to specialists who could prescribe them.

All the while it steadily raised prices. Savient put Krystexxa on the market in 2011 at $2,300 per injection. Horizon charges roughly 10 times as much. Six months of Tepezza treatment can run more than $400,000.

Horizons publicity emphasized the companys sensitivity to patients, and its constant contact with disease advocates.

Our scientists are attuned to the unmet needs of patients, their diagnostic and therapeutic journey, Bill Rees, Horizons vice president for translational sciences, told KFF Health News. Its the marrying of the basic clinical science with a focus on the needs of the patient that differetiates us.

To make sure patients keep using its drugs, clinicians say, Horizon staffers negotiate with insurance carriers, and the company offers drug discounts to lower-income patients while swaddling them with attention from its medical staff.

Horizon has a nurse talk to each and every patient before every appointment, said Dr. Brigid Freyne, who treats around half a dozen patients each year with Krystexxa at her Murrieta, California, rheumatology clinic. The patients who come in here are highly motivated to get their IV. They get the message that its very important and they are fortunate to get the medicine.

None of the manufacturers of her other infusion drugs shower patients with this kind of attention, she said.

While at Abbott, Walbert pioneered direct-to-consumer advertising for specialty drugs like Humira, a trend that aggravated insurers, who anticipated, correctly, that they would soon be shelling out billions for expensive drugs.

Horizons marketing plan for Krystexxa includes direct-to-consumer ads aimed at driving patients to specialists. The drug is designed for recalcitrant gout patients, who often have large lumps on their fingers, feet, and kidneys. Many, though not all, are heavy drinkers of beer or soda sweetened with high-fructose corn syrup, which can increase the buildup of uric acid, the cause of gout, said Dr. Robert McLean of Yale University.

While Krystexxa can help patients with advanced gout, the American College of Rheumatology views it as a drug of last resort, with plenty of cheaper, early intervention alternatives available.

I prescribe it maybe once a year, McLean said. From a cost-effectiveness standpoint, it warrants questioning.

Horizon recently started a publicity campaign addressed to all gout sufferers, urging them to see a rheumatologist or a nephrologist the specialists it has targeted with Krystexxa educational materials before the disease does too much harm.

Horizon would like you to say, Everyone with serious gout should be started on Krystexxa, said Dr. James ODell, a rheumatologist at the University of Nebraska Medical Center. The Horizon pitchmen he deals with are nice guys, but we dont believe thats the best way.

The company defends its marketing practices. We learn what matters most to patient communities and act. This approach has been validated by independent third-party research, said Riedel.

The Federal Trade Commission said in January it was seeking more information on the Amgen-Horizon merger. Sen. Elizabeth Warren (D-Mass.), citing high prices for Horizon and Amgen drugs, urged the agency to nix the deal.

Arthur Allen: ArthurA@kff.org, @ArthurAllen202 Related Topics Health Care Costs Health Industry Pharmaceuticals Drug Costs Prescription Drugs Contact Us Submit a Story Tip

Continue Reading

Sports

Hunter marks quiet day at Colorado Showcase

Published

on

By

Hunter marks quiet day at Colorado Showcase

BOULDER, Colo. — A horde of NFL talent evaluators headed for the mountains Friday for the Colorado Showcase, where Heisman Trophy winner Travis Hunter was one of the big draws.

However, it was going to be a limited look at best as Hunter was not seen when players’ heights and weights were taken or for the jumps and 40-yard dash.

Hunter, who is expected to be a top-five selection in this year’s draft and is the No. 1 player on Mel Kiper Jr.’s Big Board, was initially not expected to participate in any on-field work, but Friday morning some scouts in attendance said they expected the two-way star to run routes as a receiver for quarterback Shedeur Sanders‘ throwing session.

Hunter did not work out at the scouting combine or Big 12 pro day but did meet with teams in Indianapolis. Sanders, one of the top quarterbacks on the board and Kiper’s No. 5 player overall, also did not work out at the combine.

Sanders’ brother, Colorado safety Shilo Sanders, measured in at 5-foot-11⅞, 196 pounds, but he did not participate in the jumps or bench press that opened the workout, citing a right shoulder injury.

The highly attended event — by scouts, coaches and personnel executives as well as fans packing small bleachers — had a festive atmosphere. Colorado coach Deion Sanders named it the “We Ain’t Hard 2 Find Showcase,” completed with a large lighted “showcase” sign next to the drills.

Hunter, who has said he wants to play offense and defense in the NFL, won the Chuck Bednarik (top defensive player) and Biletnikoff (top receiver) awards, in addition to the Heisman. He said whether he would primarily be a wide receiver or cornerback in the NFL “depended on the team that picks me.”

He had 96 catches for 1,258 yards and 15 touchdowns as a receiver last season to go with 35 tackles, 11 pass breakups and four interceptions at cornerback. In the Buffaloes’ regular-season finale against Oklahoma State, he became the only FBS player in the past 25 years with three scrimmage touchdowns on offense and an interception in the same game, according to ESPN Research.

Hunter played 1,380 total snaps in Colorado’s 12 regular-season games: 670 on offense, 686 on defense and 24 on special teams. He played 1,007 total snaps in 2023.

With all NFL eyes on the Colorado campus to see Sanders throw, one player who made the most of it was wide receiver Will Sheppard, who was not invited to the combine. Sheppard, who measured in at 6-2¼, 196 pounds, ran his 40s in 4.56 and 4.54 to go with a 40½-inch vertical jump and a 10-foot-11 in the broad jump.

Continue Reading

Sports

‘It’s taken on a life of its own’: Inside the 48 hours torpedo bats launched into baseball lore

Published

on

By

'It's taken on a life of its own': Inside the 48 hours torpedo bats launched into baseball lore

At 1:54 ET on Saturday afternoon, New York Yankees play-by-play man Michael Kay lit the fuse on what will be remembered as either one of the most metamorphic conversations in baseball history or one of its strangest.

During spring training, someone in the organization had mentioned to Kay that the team’s analytics department had counseled players on where pitches tended to strike their bats, and with subsequent buy-in from some of the players, bats had been designed around that information. In the hours before the Yankees’ home game against the Brewers that day, Kay told the YES Network production staff about this, alerting them so they could look for an opportunity to highlight the equipment.

After the Yankees clubbed four homers in the first inning, a camera zoomed in on Jazz Chisholm Jr.‘s bat in the second inning. “You see the shape of Chisholm’s bat…” Kay said on air. “It’s got a big barrel on it,” Paul O’Neill responded, before Kay went on to describe the analysis behind the bat shaped like a torpedo.

Chisholm singled to left field, and after Anthony Volpe worked the count against former teammate Nestor Cortes to a full count, Volpe belted a home run to right field using the same kind of bat. A reporter watching the game texted Kay: Didn’t he hit the meat part of the bat you were talking about — just inside where the label normally is?

Yep, Kay responded. Within an hour of Kay’s commentary, the video of Chisholm’s bat and Kay’s exchange with O’Neill was posted on multiple platforms of social media, amplified over and over. What happened over the next 48 hours was what you get when you mix the power of social media and the desperation of a generation of beleaguered hitters. Batting averages are at a historic low, strikeout rates at a historic high, and on a sunny spring day in the Bronx, here were the Yankees blasting baseballs into the seats with what seemed to be a strangely shaped magic bat.

An oasis of offense had formed on the horizon, and hitters — from big leaguers to Little Leaguers, including at least one member of Congress — paddled toward it furiously. Acres of trees will be felled and shaped to feed the thirst for this new style of bats. Last weekend, one bat salesman asked his boss, “What the heck have we done?”

Jared Smith, CEO of bat-maker Victus, said, “I’ve been making bats for 15, 16 years. … This is the most talked-about thing in the industry since I started. And I hope we can make better-performing bats that work for players.”

According to Bobby Hillerich, the vice president of production at Hillerich & Bradsby, his company — which is based in Louisville, Kentucky, and makes Louisville Slugger bats — had produced 20 versions of the torpedo bat as of this past Saturday, and in less than a week, that number has tripled as players and teams continually call in their orders.

Said Yankees manager Aaron Boone: “It’s taken on a life of its own.”

play

0:36

Olney: ‘Torpedo’ bats could be catching the eye of MLB teams

Buster Olney reports on the Braves exploring the new “torpedo” bats the Yankees have been using and how other teams could explore it as well.

Even though Saturday marked its launch into the mainstream, this shape of bat has actually been around for a while. Hillerich & Bradsby had its first contact with a team about the style in 2021 and had nondisclosure agreements with four teams as the bat evolved; back then, it was referred to as the “bowling pin” bat. The Cubs’ Nico Hoerner was the first major leaguer to try it — and apparently wasn’t comfortable with it. Cody Bellinger tried it when he was with the Cubs before joining the Yankees during the offseason.

Before Atlanta took the field Sunday night, Braves catcher Drake Baldwin recalled trying one in the Arizona Fall League last year (noting that his first impression was that it “looked weird”). Mets shortstop Francisco Lindor used it in 2024, in a year in which he would finish second in the NL MVP voting; Lindor’s was a little different from Volpe’s version, with a cup hollowed out at the end of the bat. Giancarlo Stanton swung one throughout his playoff surge last fall, but no one in the media noticed, perhaps because of how the pitch-black color of Stanton’s bat camouflaged the shape.

Minnesota manager Rocco Baldelli saw one in the Twins’ dugout during spring training and picked it up, his attention drawn to the unusual shape. “What the hell is this thing?” he asked, wondering aloud whether the design was legal. When he was assured it was, he put it back down.

Baldelli’s experience reflected the way hitters have used and assessed bats since the advent of baseball: They’ll pick up bats and see how they feel, their interest fueled by the specter of success. Tony Gwynn won eight batting titles, and many teammates and opposing hitters — Barry Bonds among them — asked whether they could inspect his bats. The torpedo bat’s arrival was simply the latest version of that long-held search for the optimal tool.

On Opening Day, eight teams had some version of the torpedo bat within their stock, according to one major league source. But with video of the Yankees’ home runs being hit off unusual bats saturating social media Saturday afternoon, the phone of Kevin Uhrhan, pro bat sales rep for Louisville Slugger, blew up with requests for torpedo bats. James Rowson, the hitting coach of the Yankees, began to get text inquiries — about 100, he later estimated. Everyone wanted to know about the bat; everyone wanted to get their own.

In San Diego, Braves players asked about the bats, and by Sunday morning, equipment manager Calvin Minasian called in the team’s order. By the middle of the week, all 30 teams had asked for the bats. “Every team started trying to get orders in,” Hillerich said. “We’re trying to scramble to get wood. And then it was: How fast can we get this to retail?”

Victus produces the bats Chisholm and Volpe are using and has made them available for retail. Three senior players, all in their 70s, stopped by the Victus store to ask about the torpedoes. A member of Congress who plays baseball reached out to Louisville Slugger.

The Cincinnati Reds contacted Hillerich & Bradsby, saying, “We need you in Cincinnati on Monday ASAP,” and soon after, Uhrhan and pro bat production manager Brian Hillerich, Bobby’s brother, made the 90-minute drive from the company’s factory in Louisville with test bats.

Reds star Elly De La Cruz tried a few, decided on a favorite and used it for a career performance that night.

“You can think in New York, maybe there was wind,” Bobby Hillerich said. “Elly hits two home runs and gets seven RBIs. That just took it to a whole new level.”

A few days after the Yankees’ explosion, Aaron Leanhardt, who had led New York’s effort to customize its bats as a minor league hitting coordinator before being hired by the Marlins as their field coordinator, was in the middle of a horseshoe of reporters, explaining the background. “There are a lot more cameras here today than I’m used to,” he said, laughing.

Stanton spoke with reporters about the simple concept behind the bat: build a design for where a hitter is most likely to make contact. “You wonder why no one has thought of it before, for sure,” Stanton said. “I didn’t know if it was, like, a rule-based thing of why they were shaped like that.”

Over and over, MLB officials assured those asking: Yes, the bats are legal and meet the sport’s equipment specifications. Trevor Megill, the Brewers’ closer, complained about the bats, calling them like “something used in slow-pitch softball,” but privately, baseball officials were thrilled by the possibility of seeing offense goosed, something they had been attempting through rule change in recent years.

“It’s all the rage right now, given what transpired over the weekend,” said Jeremy Zoll, assistant general manager of the Twins. “I’m sure more and more guys are going to experiment with it as a result, just to see if it’s something they like.”

That personal preference is a factor for which some front office types believe the mass orders of the bats don’t account: The Yankees’ recommendations to each hitter were based on months of past data of how that player tended to strike the ball. This was not about a one-size-fits all bat; it was about precise bat measurements that reflected an individual player’s swing.

“I had never heard of it. I’ve used the same bat for nine years, so I think I’ll stick with that,” White Sox outfielder Andrew Benintendi said. “It’s pretty interesting. It makes sense. If it works for a guy, good for him. If it doesn’t, stick with what you got.”

As longtime player Eric Hosmer explained on the “Baseball Tonight” podcast, the process is a lot like what players can do in golf: look for clubs customized for a player’s particular swing. And, he added, hitting coaches might begin to think more about which bat might be most effective against particular pitchers. If a pitcher tends to throw inside, a torpedo bat could be more effective; if a pitcher is more effective outside, maybe a larger barrel would be more appropriate.

That’s the key, according to an agent representing a player who ordered a bat: “You need years of hitting data in the big leagues to dial it in and hopefully get a better result. He’s still tinkering with it; he may not even use it in a game. … I think of it like switching your irons in golf to blades: It will feel a little different and take some adjusting, and it may even change your swing subtly.”

Two days after the home run explosion, Boone said, “You’re just trying to just get what you can on the margins, move the needle a little bit. And that’s really all you’re going to do. I don’t think this is some revelation to where we’re going to be — it’s not related to the weekend that we had, for example. I don’t think it’s that. Maybe in some cases, for some players it may help them incrementally. That’s how I view it.”

“I’m kind of starting to smile at it a little more … a lot of things that aren’t real.”

Said the player agent: “It’s not an aluminum bat with plutonium in it like everyone is making it out to be.”

Reliever Adam Ottavino watched this all play out, with his 15 years of experience. “It’s the Yankees and they scored a million runs in the first few games, and it’s cool to hate the Yankees and it’s cool to look for the bogeyman,” Ottavino said, “and that’s what some people are going to do, and [you] can’t really stop that. But there’s also a lot of misinformation and noneducation on it too.”

Major league baseball mostly evolves at a glacial pace. For example, the sport is well into the second century of complaints about the surface of the ball and the debate over financial disparity among teams. From time to time, however, baseball has its eclipses, moments that command full attention and inspire change. On a “Sunday Night Baseball” game on May 18, 2008, an umpire’s botched home run call at Yankee Stadium compelled MLB to implement the first instant replay. Buster Posey’s ankle was shattered in a home plate collision in May 2011, imperiling the career of the young star, and new rules about that type of play were rewritten.

The torpedo bat eruption could turn out to be transformative, a time when the industry became aware how a core piece of equipment has been taken for granted and aware that bats could be more precisely designed to augment the ability of each hitter. Or this could all turn out to be a wild overreaction to an outlier day of home runs against a pitching staff having a really bad day.

On Thursday, Cortes — who had been hammered for five homers over two innings in Yankee Stadium — shut out the Reds for six innings.

In Baltimore, Bregman, who had tried the torpedo bat earlier this week, reverted to his usual stock and had three hits against the Orioles, including a home run. Afterward, Bregman said, “It’s the hitter. Not the bat.”

This story was also reported by Jeff Passan, Jorge Castillo, Jesse Rogers and Kiley McDaniel.

Continue Reading

Sports

What are torpedo bats? Are they legal? What to know about MLB’s hottest trend

Published

on

By

What are torpedo bats? Are they legal? What to know about MLB's hottest trend

The opening weekend of the 2025 MLB season was taken over by a surprise star — torpedo bats.

The bowling pin-shaped bats became the talk of the sport after the Yankees’ home run onslaught on the first Saturday of the season put it in the spotlight and the buzz hasn’t slowed since.

What exactly is a torpedo bat? How does it help hitters? And how is it legal? Let’s dig in.

Read: An MIT-educated professor, the Yankees and the bat that could be changing baseball


What is a torpedo bat and why is it different from a traditional MLB bat?

The idea of the torpedo bat is to take a size format — say, 34 inches and 32 ounces — and distribute the wood in a different geometric shape than the traditional form to ensure the fattest part of the bat is located where the player makes the most contact. Standard bats taper toward an end cap that is as thick diametrically as the sweet spot of the barrel. The torpedo bat moves some of the mass on the end of the bat about 6 to 7 inches lower, giving it a bowling-pin shape, with a much thinner end.


How does it help hitters?

The benefits for those who like swinging with it — and not everyone who has swung it likes it — are two-fold. Both are rooted in logic and physics. The first is that distributing more mass to the area of most frequent contact aligns with players’ swing patterns and provides greater impact when bat strikes ball. Players are perpetually seeking ways to barrel more balls, and while swings that connect on the end of the bat and toward the handle probably will have worse performance than with a traditional bat, that’s a tradeoff they’re willing to make for the additional slug. And as hitters know, slug is what pays.

The second benefit, in theory, is increased bat speed. Imagine a sledgehammer and a broomstick that both weigh 32 ounces. The sledgehammer’s weight is almost all at the end, whereas the broomstick’s is distributed evenly. Which is easier to swing fast? The broomstick, of course, because shape of the sledgehammer takes more strength and effort to move. By shedding some of the weight off the end of the torpedo bat and moving it toward the middle, hitters have found it swings very similarly to a traditional model but with slightly faster bat velocity.


Why did it become such a big story so early in the 2025 MLB season?

Because the New York Yankees hit nine home runs in a game Saturday and Michael Kay, their play-by-play announcer, pointed out that some of them came from hitters using a new bat shape. The fascination was immediate. While baseball, as an industry, has implemented forward-thinking rules in recent seasons, the modification to something so fundamental and known as the shape of a bat registered as bizarre. The initial response from many who saw it: How is this legal?


OK. How is this legal?

Major League Baseball’s bat regulations are relatively permissive. Currently, the rules allow for a maximum barrel diameter of 2.61 inches, a maximum length of 42 inches and a smooth and round shape. The lack of restrictions allows MLB’s authorized bat manufacturers to toy with bat geometry and for the results to still fall within the regulations.


Who came up with the idea of using them?

The notion of a bowling-pin-style bat has kicked around baseball for years. Some bat manufacturers made smaller versions as training tools. But the version that’s now infiltrating baseball goes back two years when a then-Yankees coach named Aaron Leanhardt started asking hitters how they should counteract the giant leaps in recent years made by pitchers.

When Yankees players responded that bigger barrels would help, Leanhardt — an MIT-educated former Michigan physics professor who left academia to work in the sports industry — recognized that as long as bats stayed within MLB parameters, he could change their geometry to make them a reality. Leanhardt, who left the Yankees to serve as major league field coordinator for the Miami Marlins over the winter, worked with bat manufacturers throughout the 2023 and 2024 seasons to make that a reality.


When did it first appear in MLB games?

It’s unclear specifically when. But Yankees slugger Giancarlo Stanton used a torpedo bat last year and went on a home run-hitting rampage in October that helped send the Yankees to the World Series. New York Mets star Francisco Lindor also used a torpedo-style bat last year and went on to finish second in National League MVP voting.


Who are some of the other notable early users of torpedo bats?

In addition to Stanton and Lindor, Yankees hitters Anthony Volpe, Austin Wells, Jazz Chisholm Jr., Cody Bellinger and Paul Goldschmidt have used torpedoes to great success. Others who have used them in games include Tampa Bay’s Junior Caminero, Minnesota’s Ryan Jeffers and Toronto’s Davis Schneider. And that’s just the beginning. Hundreds more players are expected to test out torpedoes — and perhaps use them in games — in the coming weeks.


How is this different from a corked bat?

Corking bats involves drilling a hole at the end of the bat, filling it in and capping it. The use of altered bats allows players to swing faster because the material with which they replace the wood — whether it’s cork, superballs or another material — is lighter. Any sort of bat adulteration is illegal and, if found, results in suspension.


Could a rule be changed to ban them?

Could it happen? Sure. Leagues and governing bodies have put restrictions on equipment they believe fundamentally altered fairness. Stick curvature is limited in hockey. Full-body swimsuits made of polyurethane and neoprene are banned by World Aquatics. But officials at MLB have acknowledged that the game’s pendulum has swung significantly toward pitching in recent years, and if an offensive revolution comes about because of torpedo bats — and that is far from a guarantee — it could bring about more balance to the game. If that pendulum swings too far, MLB could alter its bat regulations, something it has done multiple times already this century.


So the torpedo bat is here to stay?

Absolutely. Bat manufacturers are cranking them out and shipping them to interested players with great urgency. Just how widely the torpedo bat is adopted is the question that will play out over the rest of the season. But it has piqued the curiosity of nearly every hitter in the big leagues, and just as pitchers toy with new pitches to see if they can marginally improve themselves, hitters will do the same with bats.

Comfort is paramount with a bat, so hitters will test them during batting practice and in cage sessions before unleashing them during the game. As time goes on, players will find specific shapes that are most comfortable to them and best suit their swing during bat-fitting sessions — similar to how golfers seek custom clubs. But make no mistake: This is an almost-overnight alteration of the game, and “traditional or torpedo” is a question every big leaguer going forward will ask himself.

Continue Reading

Trending